Closed · RFA-CA-25-003 · CFDA 93.394 · Discretionary
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $150K
- Award range
- Closed
- Status
- December 9, 2025
- Close date
- 4
- Expected awards
The verdict
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $150,000 across 4 expected awards. Future funding cycles may be published under the same CFDA number.
- up to $150K
- award range
- Closed
- application status
- 4
- expected awards
- 93.394
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) - is cataloged under number RFA-CA-25-003 and tied to CFDA assistance listing 93.394, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on December 16, 2024 and last updated on December 9, 2025. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $150,000. The agency has projected $150,000 in total estimated funding for this announcement. It expects to issue 4 awards. If the agency funds the expected 4 awards from the $150,000 estimated pool, the average award works out to roughly $38,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on December 9, 2025. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $150,000
Close Date
December 9, 2025
Posted
December 16, 2024
Est. Total Funding
$150,000
Expected Awards
4
Instrument
Grant
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |